Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE: 300119)
Health Care · Pharmaceuticals · CN
CN¥17.92
-6.91% today · -23.7% 1Y
Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE: 300119) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.21B and employs 2,803 people.
Over the last twelve months the share price has lost 23.7%, trading between 13.91 and 23.51.
Tweenvest scores Tianjin Ringpu Bio-Technology Co.,Ltd. across four factors: quality 77/100, value 56/100, growth 51/100, dividend 39/100. Its strongest factor is quality.
300119 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.21B
- Revenue (TTM)
- $493.37M
- P/E
- 20.74
- EPS
- 0.86
- Dividend yield
- 2.23%
- Beta (5Y)
- 0.12
- 52-week high
- CN¥23.51
- 52-week low
- CN¥13.91
- Avg volume (3M)
- —
- Shares outstanding
- 454.07M
- Employees
- 2,803
- Next earnings
- —
About Tianjin Ringpu Bio-Technology Co.,Ltd.
Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of a broad spectrum of animal health solutions. Their product portfolio includes veterinary biologicals, pharmaceutical formulations, functional feed additives, and active pharmaceutical ingredients (APIs) for the Chinese market. The company provides a wide array of vaccines and medications for livestock, particularly poultry and swine. They also offer a comprehensive line of pet care products, such as inactivated rabies vaccines, recombinant canine-alpha interferon, inhalation anesthetics like isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate injections for bacterial infections, and cardiac treatments including napril chewable tablets. For waterfowl, their specialized offerings include live and inactivated duck tempusu vaccines, purified egg yolk antibodies for gosling plague and duck viral hepatitis, duck infectious serositis inactivated vaccines, as well as injectable and soluble powder treatments like florfenicol and kanamycin. Furthermore, Ringpu develops antifungal products featuring natural plant extracts, immune polysaccharides, probiotics (such as Clostridium butyricum and Lactobacillus plantarum), antibacterial peptides, enzyme preparations, and acidulants. Their disinfection and cleaning range comprises potassium hydrogen persulfate composite powder, various quaternary ammonium compounds (e.g., benzyl trimethyl ammonium chloride, deca methyl ammonium bromide), sodium dichloroisocyanurate, and iodine glycerin solutions. The company's API production includes crucial ingredients like tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, and gamimycin.
- ISIN
- CNE100000TV1
- Founded
- 1998
- Listed since
- Sep 17, 2010
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,246.02 | -0.75% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.63 | +0.88% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.68 | -1.23% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.04 | -0.12% |
Figures last refreshed Aug 18, 2026.